(Total Views: 744)
Posted On: 12/26/2020 3:25:34 AM
Post# of 149431
Re: ClosetInvestor #69724
I don't think your question --
makes any sense. The trial is blinded to Cytodyn, and the results of the earlier EINDs are anecdotal, so the company couldn't possibly offer efficacy data. Which would mean there would be no point in providing guidance for open label.
You're suggesting something might be true that couldn't be true. No point in suggesting it.
Quote:--
does an application for open label extension require efficacy data? If so, what data is CYDY planning on applying with?
makes any sense. The trial is blinded to Cytodyn, and the results of the earlier EINDs are anecdotal, so the company couldn't possibly offer efficacy data. Which would mean there would be no point in providing guidance for open label.
You're suggesting something might be true that couldn't be true. No point in suggesting it.
(4)
(0)Scroll down for more posts ▼
